Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 8Plasma cell 4Other hematologic neoplasm 2Thoracic 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1

Conditions

Multiple Myeloma 4Recurrence 1Cytokine Release Syndrome 1

Interventions

Dexamethasone 47Lenalidomide 31daratumumab 24Bortezomib 23pomalidomide 19carfilzomib 15Specimen Handling 15Cyclophosphamide 15Calcium Dobesilate 15Biopsy 15Magnetic Resonance Spectroscopy 11talquetamab 9isatuximab 9Melphalan 9iberdomide 8dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8fludarabine 7belantamab mafodotin 7selinexor 5X-Rays 5tocilizumab 4fludarabine phosphate 4elotuzumab 4Nuclear Medicine Department, Hospital 4trametinib 3dabrafenib 3Whole-Body Irradiation 3Thalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
tocilizumab × Plasma cell × 30 days × Clear all
NCT05583617 2026-06-03

PLYCOM

Hoffmann-La Roche

Phase 1/2 Recruiting
200 enrolled
Plasma cell

Multiple Myeloma

NCT05927571 2026-06-03

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Genentech, Inc.

Phase 1 Recruiting
120 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07609940 2026-05-27

POPLIN

Regeneron Pharmaceuticals

Phase 4 Not yet recruiting
30 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT07589634 2026-05-15

TRI Pro

Janssen Research & Development, LLC

Phase 2 Not yet recruiting
230 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡